Advancements in Personalized Cellular Immunotherapy

Advancements in Personalized Cellular Immunotherapy: A Comprehensive Guide to Cancer Treatment is an authoritative guide that delves into the foundational principles, recent advancements, and clinical applications of this innovative treatment approach, aiming to bridge the gap between research and clinical practice. It offers a thorough analysis of the mechanisms of action, therapeutic efficacy, and safety profiles of various cellular immunotherapy modalities, enabling clinicians to make well-informed treatment decisions and optimize patient outcomes. The book promotes interdisciplinary collaboration by bringing together experts from oncology, immunology, molecular biology, and translational medicine. Through detailed case studies, clinical guidelines, and practical insights, it provides healthcare professionals with the knowledge and tools needed to effectively incorporate cellular immunotherapy into standard oncology practice. Additionally, the book addresses key challenges and future directions in the field, such as strategies to enhance treatment efficacy, overcome resistance mechanisms, and broaden the accessibility of cellular immunotherapy to more patients. Advancements in Personalized Cellular Immunotherapy: A Comprehensive Guide to Cancer Treatment aims to educate and empower healthcare professionals, fostering continued innovation and collaboration to improve cancer care and patient outcomes.

Arun Kumar Singh holds an M.Pharm in Pharmaceutics from Galgotias University, India, and serves as an Assistant Professor in the Department of Pharmacy at Vivekanand Global University. He is actively engaged in teaching and interdisciplinary research spanning nano-formulation, artificial intelligence, machine learning, big data analytics, IoT, blockchain, cancer biology, and neuroscience. Mr. Singh has made substantial scholarly contributions, authoring one book with IOP Publishing, five book chapters with River Publishers, and 28 review articles in reputed journals, including high-impact publications in Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. In addition, he has authored and edited 58 books with leading publishers such as Elsevier, CRC Press, and Wiley. Known for his research acumen and leadership, Mr. Singh is committed to advancing pharmaceutical sciences through innovation and interdisciplinary collaboration, with a focus on impactful healthcare solutions. Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy. Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, includ